The Lightning Round is extended in this CNBC.com exclusive feature.
Believe it or not, there is some good news regarding health care reform. Legislators, employers and employees are actually in agreement on a number of important issues facing the industry. If only both political parties in our legislature could come together to implement changes that are not controversial, perhaps the remaining disagreeable items could be tackled later.
Why Cramer thinks this space has lost its luster and what he recommends playing instead.
The world’s largest medical device company, Johnson & Johnson, expects to have all the products recalled last year on the shelves again by the end of this year, William Weldon, CEO of Johnson and Johnson, told CNBC Thursday.
Onyx Pharmaceuticals CEO Tony Coles reveals the next two areas to watch in the Biotech sector.
Cramer makes the call on viewers' favorite stocks.
US health-care reform has cost the pharmaceutical company Glaxo SmithKline (GSK) millions of dollars in lost sales, a trend expected to continue in the near term, Andrew Witty, its CEO, told CNBC Thursday.
Why Doug Thomas, an analyst with JET Investment Research, thinks the underwear maker is oversold.
The renown hedge fund manager is said to be considering taking a share in this retailer, thereby creating some unusual options activity, reports "DRJ."
Genzyme and Sanofi-Aventis have reached a so called “agreement in principle” for a deal in which Sanofi will acquire Genzyme.
The biotech firm reported a profit that surpassed what analysts expected Monday, but issued a 2011 earnings outlook that was below what Wall Street forecasts.
It’s shaping up to be a long fight. I’m talking about Community Health Systems’ hostile bid for Tenet Healthcare.
Latin America is a “very underestimated area of opportunity” for business, Chris Viehbacher, CEO of the drugmaker Sanofi-Aventis, told CNBC Tuesday.
Tackling the subject of improving health is complex and to know where we can have the most effect, sparks a lengthy and challenging debate. As the world continues to evolve, science will continue to offer exciting new discoveries. But it will also see the appearance of new diseases, the evolution of existing diseases and the re-emergence of old diseases to continually challenge the state of our health. However, for me, it is chronic disease that is the biggest healthcare challenge facing us, which has been largely unforeseen and is not being addressed adequately.
Mail-order drug pharmacy Medco Health Solutions will have a “monster” year, meaning a very lucrative one, in 2012, due to a number of blockbuster drugs going off-patent, David Snow, its CEO and chairman, told CNBC Monday.
A growing form of radiation therapy injures patients when its pinpoint beam is allowed to spread too far. The New York Times reports.
The "Mad Money" host explains why getting past this key level means stocks could go higher still.
Investors sent shares of diet drug makers soaring Wednesday, one day after an FDA advisory panel recommended approval of Orexigen Therapeutic's weight loss drug Contrave.
Despite the declaration that the “ingredients are there” for a deal between Genzyme Corp and Sanofi-Aventis but at a higher price, consensus among investors seem to be that Sanofi won’t be raising their bid of $69/share
Congress will tweak but not repeal health care legislation, insurers won't take a bit hit from reform measures, sector consolidation will continue and China will drive growth for drug and device makers.